• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

使用血尿患者风险识别计算器对尿路肿瘤进行估计预测。

Estimated prediction of urinary tract neoplasms using the identify risk calculator in patients with haematuria.

作者信息

Hidalgo Beatriz Gutiérrez, Rivas Juan Gómez, de la Parra Irene, Arévalo Rommel, Romo M Isabel Galante, Ciappara Marco, Redondo Enrique, Moreno-Sierra Jesús

机构信息

Department of Urology, Hospital Clínico San Carlos, Complutense University, Madrid, Spain.

Health Research Institute, Hospital Clínico San Carlos, Madrid, Spain.

出版信息

Cent European J Urol. 2024;77(4):612-617. doi: 10.5173/ceju.2024.0113. Epub 2024 Dec 28.

DOI:10.5173/ceju.2024.0113
PMID:40313698
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12042406/
Abstract

INTRODUCTION

The classification of patients studied for haematuria into risk groups is important for early diagnosis of urinary tract cancers and optimising healthcare resources. This study aims to evaluate the role of the IDENTIFY calculator in the initial study of these patients and its use for classifying patients into risk groups.

MATERIAL AND METHODS

A study of patients with haematuria was performed from June 2020 to June 2022. They were classified into risk groups using the IDENTIFY calculator. Final diagnosis of bladder neoplasia between the risk groups was compared. Receiver operating characteristic (ROC) curves were calculated according to the percentage of risk obtained with the calculator and the final diagnosis of bladder neoplasia.

RESULTS

We included 255 patients. Imaging tests were positive for bladder cancer in 39 patients (15.3%). Transurethral resection of bladder tumour was performed in 39 cases; 4 were negative, 18 cases Ta, 2 cases T1, 14 cases T2, and one case carcinoma (CIS). The final diagnosis was bladder neoplasia in 35 patients (13.8%). These patients were classified as: one low risk (2.9%), 4 intermediate risk (11.4%), and 30 high risk (85.7%); p <0.001. ROC curves were calculated, with an AUC (area under curve) of 0.89; p <0.001.

CONCLUSIONS

Patients classified into the high-risk group were more frequently diagnosed with bladder cancer than other risk groups. The IDENTIFY risk calculator is a simple and easy-to-use tool with acceptable discrimination in the diagnosis of urinary tract tumours, specifically bladder cancer.

摘要

引言

将血尿患者分为不同风险组对于泌尿系统癌症的早期诊断和优化医疗资源非常重要。本研究旨在评估IDENTIFY计算器在这些患者初步研究中的作用及其用于将患者分类为不同风险组的情况。

材料与方法

对2020年6月至2022年6月期间的血尿患者进行了一项研究。使用IDENTIFY计算器将他们分为不同风险组。比较了不同风险组之间膀胱肿瘤的最终诊断情况。根据计算器得出的风险百分比和膀胱肿瘤的最终诊断绘制了受试者操作特征(ROC)曲线。

结果

我们纳入了255例患者。39例患者(15.3%)的影像学检查显示膀胱癌阳性。39例患者进行了经尿道膀胱肿瘤切除术;4例为阴性,18例为Ta期,2例为T1期,14例为T2期,1例为原位癌(CIS)。最终诊断为膀胱肿瘤的患者有35例(13.8%)。这些患者被分类为:1例低风险(2.9%),4例中风险(11.4%),30例高风险(85.7%);p<0.001。计算了ROC曲线,曲线下面积(AUC)为0.89;p<0.001。

结论

与其他风险组相比,被分类为高风险组的患者更常被诊断为膀胱癌。IDENTIFY风险计算器是一种简单易用的工具,在泌尿系统肿瘤尤其是膀胱癌的诊断中具有可接受的鉴别能力。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8832/12042406/918ecf71694e/CEJU-77-2024.0113-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8832/12042406/4b9c89534870/CEJU-77-2024.0113-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8832/12042406/918ecf71694e/CEJU-77-2024.0113-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8832/12042406/4b9c89534870/CEJU-77-2024.0113-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8832/12042406/918ecf71694e/CEJU-77-2024.0113-g002.jpg

相似文献

1
Estimated prediction of urinary tract neoplasms using the identify risk calculator in patients with haematuria.使用血尿患者风险识别计算器对尿路肿瘤进行估计预测。
Cent European J Urol. 2024;77(4):612-617. doi: 10.5173/ceju.2024.0113. Epub 2024 Dec 28.
2
Machine Learning and External Validation of the IDENTIFY Risk Calculator for Patients with Haematuria Referred to Secondary Care for Suspected Urinary Tract Cancer.针对因疑似尿路癌转诊至二级医疗机构的血尿患者,IDENTIFY风险计算器的机器学习与外部验证
Eur Urol Focus. 2024 Dec;10(6):1034-1042. doi: 10.1016/j.euf.2024.06.004. Epub 2024 Jun 21.
3
Developing a Diagnostic Multivariable Prediction Model for Urinary Tract Cancer in Patients Referred with Haematuria: Results from the IDENTIFY Collaborative Study.为血尿转诊患者开发尿路癌诊断多变量预测模型:IDENTIFY合作研究结果
Eur Urol Focus. 2022 Nov;8(6):1673-1682. doi: 10.1016/j.euf.2022.06.001. Epub 2022 Jun 25.
4
Does urinary cytology have a role in haematuria investigations?尿细胞学检查在血尿检查中有作用吗?
BJU Int. 2019 Jan;123(1):74-81. doi: 10.1111/bju.14459. Epub 2018 Aug 29.
5
Can re-cTURBT be useful in pT1HG disease as a risk indicator of recurrence and progression? A single centre experience.再次经尿道膀胱肿瘤切除术(re-cTURBT)作为pT1期高级别(HG)疾病复发和进展的风险指标是否有用?一项单中心经验。
Arch Ital Urol Androl. 2017 Dec 31;89(4):272-276. doi: 10.4081/aiua.2017.4.272.
6
Microscopic haematuria at time of diagnosis is associated with lower disease stage in patients with newly diagnosed bladder cancer.新诊断的膀胱癌患者在诊断时出现镜下血尿与较低的疾病分期相关。
BJU Int. 2016 May;117(5):783-6. doi: 10.1111/bju.13345. Epub 2015 Oct 29.
7
European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ).欧洲泌尿外科学会非肌层浸润性膀胱癌(Ta、T1和原位癌)指南
Eur Urol. 2022 Jan;81(1):75-94. doi: 10.1016/j.eururo.2021.08.010. Epub 2021 Sep 10.
8
Image directed redesign of bladder cancer treatment pathways: the BladderPath RCT.影像指导膀胱癌治疗路径再设计:膀胱癌路径 RCT。
Health Technol Assess. 2024 Aug;28(42):1-65. doi: 10.3310/DEHT5407.
9
Diagnostic tests and algorithms used in the investigation of haematuria: systematic reviews and economic evaluation.用于血尿调查的诊断测试和算法:系统评价与经济评估
Health Technol Assess. 2006 Jun;10(18):iii-iv, xi-259. doi: 10.3310/hta10180.
10
Evaluation of diagnostic strategies for bladder cancer using computed tomography (CT) urography, flexible cystoscopy and voided urine cytology: results for 778 patients from a hospital haematuria clinic.使用计算机断层扫描(CT)尿路造影、软性膀胱镜检查和尿液细胞学检查评估膀胱癌的诊断策略:来自医院血尿诊所的 778 例患者的结果。
BJU Int. 2012 Jul;110(1):84-94. doi: 10.1111/j.1464-410X.2011.10664.x. Epub 2011 Nov 28.

本文引用的文献

1
European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ)-A Summary of the 2024 Guidelines Update.欧洲泌尿外科学会非肌层浸润性膀胱癌(TaT1和原位癌)指南——2024年指南更新摘要
Eur Urol. 2024 Dec;86(6):531-549. doi: 10.1016/j.eururo.2024.07.027. Epub 2024 Aug 17.
2
Machine Learning and External Validation of the IDENTIFY Risk Calculator for Patients with Haematuria Referred to Secondary Care for Suspected Urinary Tract Cancer.针对因疑似尿路癌转诊至二级医疗机构的血尿患者,IDENTIFY风险计算器的机器学习与外部验证
Eur Urol Focus. 2024 Dec;10(6):1034-1042. doi: 10.1016/j.euf.2024.06.004. Epub 2024 Jun 21.
3
The impact of antithrombotic therapy on the time of detection of bladder cancer.
抗血栓治疗对膀胱癌检测时间的影响。
Cent European J Urol. 2023;76(1):33-37. doi: 10.5173/ceju.2022.193. Epub 2022 Dec 22.
4
Upper Tract Urinary Carcinoma: A Unique Immuno-Molecular Entity and a Clinical Challenge in the Current Therapeutic Scenario.上尿路尿路上皮癌:当前治疗方案中的独特免疫-分子实体和临床挑战。
Technol Cancer Res Treat. 2023 Jan-Dec;22:15330338231159753. doi: 10.1177/15330338231159753.
5
Biomarkers to assess the risk of bladder cancer in patients presenting with haematuria are gender-specific.用于评估血尿患者膀胱癌风险的生物标志物具有性别特异性。
Front Oncol. 2022 Sep 23;12:1009014. doi: 10.3389/fonc.2022.1009014. eCollection 2022.
6
Developing a Diagnostic Multivariable Prediction Model for Urinary Tract Cancer in Patients Referred with Haematuria: Results from the IDENTIFY Collaborative Study.为血尿转诊患者开发尿路癌诊断多变量预测模型:IDENTIFY合作研究结果
Eur Urol Focus. 2022 Nov;8(6):1673-1682. doi: 10.1016/j.euf.2022.06.001. Epub 2022 Jun 25.
7
Systematic Review of the Incidence of and Risk Factors for Urothelial Cancers and Renal Cell Carcinoma Among Patients with Haematuria.血尿患者尿路上皮癌和肾细胞癌的发病率及危险因素的系统评价。
Eur Urol. 2022 Aug;82(2):182-192. doi: 10.1016/j.eururo.2022.03.027. Epub 2022 Apr 5.
8
The IDENTIFY study: the investigation and detection of urological neoplasia in patients referred with suspected urinary tract cancer - a multicentre observational study.IDENTIFY 研究:疑似尿路癌症患者的泌尿系统肿瘤的调查和检测-一项多中心观察性研究。
BJU Int. 2021 Oct;128(4):440-450. doi: 10.1111/bju.15483. Epub 2021 Sep 8.
9
Diagnosis and Staging of Bladder Cancer.膀胱癌的诊断和分期。
Hematol Oncol Clin North Am. 2021 Jun;35(3):531-541. doi: 10.1016/j.hoc.2021.02.004. Epub 2021 Apr 15.
10
The Approach to the Patient with Hematuria.血尿患者的诊疗方法
Emerg Med Clin North Am. 2019 Nov;37(4):755-769. doi: 10.1016/j.emc.2019.07.011.